<DOC>
	<DOCNO>NCT01523860</DOCNO>
	<brief_summary>This prospective , multicenter phase II trial design determine efficacy safety brief chemoimmunotherapy combination Rituximab + Bendamustine + Mitoxantrone elderly patient advance stage Follicular Lymphoma .</brief_summary>
	<brief_title>Brief Chemoimmunotherapy With R+B+M Followed R Elderly Patients Advanced Stage Untreated Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histological proven diagnosis Bcell CD20+ follicular NHL , grade I , II IIIa WHO Classification Untreated patient exception prior limited radiotherapy Stage III IV require therapy accord SIE GELF criterion Stage II least one following : Bulky disease ( &gt; 7 cm ) LDH &gt; normal Systemic symptom Beta2Microglobulin &gt; 3 mg/l Extranodal involvement Active disease rapid progression 5.Age 65 80 year , geriatric score `` FIT '' ( see Appendix B ) 6.Life expectancy &gt; 6 month 7.ECOG performance status 02 ( see Appendix C ) 8.LVEF ≥45 % FS ≥37 % 9.ANC ≥1 x 109/l Platelets count ≥75 x 109/l , unless due bone marrow involvement follicular lymphoma 10.Creatinine 1.5 x ULN 11.Conjugated bilirubin 2 x ULN 12.Alkaline phosphatase transaminases 2 x ULN 13.Sending bone marrow sample Bcl2/IgH rearrangement evaluation 14.Written informed content Men agree take adequate contraceptive precaution least 6 month cessation therapy History malignancy within 3 year prior study entry except : adequately treat carcinoma situ cervix ; basal squamous cell skin cancer ; low grade , early stage , localized prostate cancer treat surgically curative intent ; good prognosis DCIS breast treat lumpectomy alone curative intent Medical condition require long term use ( &gt; 1 month ) systemic corticosteroid Active bacterial , viral , fungal infection require systemic therapy 5 . Concurrent medical condition might exclude administration therapy Cardiac insufficiency ( NYHA grade III/IV ; see Appendix D ) Myocardial infarction within 6 month entry study Severe chronic obstructive pulmonary disease hypoxemia Severe diabetes mellitus difficult control adequate insulin therapy Hypertension difficult control Impaired renal function creatinine clearance &lt; 30 ml/min ( see Appendix E ) HIV positivity HBV positivity exception patient HbsAg negative Ab antiHbcore positive ( patient need receive prophylaxis Lamivudine ) HCV positivity exception patient laboratory sign active chronic hepatitis HCVRNA negativity CNS involvement lymphoma 16 . Participation time another study investigational drug use Known hypersensitivity anaphylactic reaction murine antibody proteins Any coexist medical psychological condition would preclude participation study compromise ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>